{"filings":[{"id":67843,"accession_number":"0001193125-26-221567","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-05-13T20:02:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.","Total revenue of $0.3M, down from $5.9M in prior-year quarter.","Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.","GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.","R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion."],"consensus_eps_estimate":-0.1836,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107440,"accession_number":"0001193125-26-126244","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.","Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.","Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).","Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.","Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107439,"accession_number":"0001193125-26-032004","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Director resigns; SEC concludes investigation with no enforcement action","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.","Company intends to enter consulting agreement with Mahadevia for continued support.","SEC concluded its investigation on Jan 20, 2026; will not recommend enforcement action against company at this time.","Investigation was previously disclosed in SEC periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123783,"accession_number":"0001193125-25-325821","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GSK files NDA resubmission for tebipenem HBr; Spero to receive $25M milestone in Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["GSK resubmitted NDA to FDA for oral carbapenem tebipenem HBr for cUTI/pyelonephritis.","Resubmission triggers $25 million milestone payment to Spero, expected Q1 2026.","Spero's tebipenem HBr is investigational; approval not guaranteed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123782,"accession_number":"0001193125-25-280518","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.","Cash and equivalents $48.6M as of Sep 30, 2025; company expects funding into 2028.","Phase 3 PIVOT-PO trial of tebipenem HBr met primary endpoint; GSK to submit NDA to FDA in Q4 2025 with decision expected 2H 2026.","SPR720 program for NTM pulmonary disease discontinued in Q3 2025 after Phase 2a/1 data review.","R&D expenses fell to $8.6M from $26.9M due to lower PIVOT-PO and SPR720 costs."],"consensus_eps_estimate":-0.255,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":25505000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140463,"accession_number":"0001193125-25-178970","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.","Phase 3 PIVOT-PO trial of tebipenem HBr in cUTI met primary endpoint; IDMC stopped early for efficacy.","Spero and GSK plan to submit data to FDA in 2H 2025; potential milestone payments adjusted to up to $101M from $150M.","Cash $31.2M at June 30 plus $23.8M GSK milestone received Aug 2025; runway expected into 2028.","Esther Rajavelu appointed CEO/President effective May 2, 2025, continuing as CFO."],"consensus_eps_estimate":-0.3876,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":20063000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158147,"accession_number":"0001193125-25-142807","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Spero Therapeutics stockholders approve 3M share increase to 2017 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan increasing authorized shares by 3,000,000.","Reelected Class II directors Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu to 2028 meeting.","Ratified PricewaterhouseCoopers as independent auditor for fiscal year 2025.","Advisory vote on executive compensation passed with 25.2M for, 0.6M against.","Quorum of 40,015,633 shares (71.57%) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158146,"accession_number":"0001193125-25-128680","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spero/GSK Phase 3 PIVOT-PO trial for tebipenem HBr meets primary endpoint, stops early for efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tebipenem HBr met non-inferiority vs IV imipenem-cilastatin in 1,690 cUTI patients; IDMC recommended early stop.","No new safety concerns; diarrhea and headache most common adverse events.","GSK plans FDA filing in second half 2025; could be first oral carbapenem for cUTIs in US.","cUTIs affect ~2.9M US cases/year with >$6B in healthcare costs; IV-only standard currently.","Supported by BARDA funding and QIDP/Fast Track designations from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158145,"accession_number":"0001193125-25-118882","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.","Cash $48.9M plus $23.75M earned GSK milestone payments provides runway into Q2 2026.","Esther Rajavelu appointed President & CEO effective May 2, 2025; continues as CFO & Treasurer.","Phase 3 PIVOT-PO interim analysis for tebipenem HBr expected Q2 2025; SPR720 program suspended after missing endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":5874000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158144,"accession_number":"0001193125-25-100433","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.","Rajavelu continues as CFO and Treasurer; base salary $620K, target bonus 50%, 185,000 RSUs vesting over 4 years.","Former CEO Sath Shukla mutually separates; receives salary continuation of $615,825, cash bonus $307,913, and retention bonus $452,813.","Company expects update on PIVOT-PO Phase 3 trial for tebipenem HBr this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176512,"accession_number":"0001193125-25-065633","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q4 net loss of $20.9M; revenue down 80% YoY; pipeline setbacks and SEC Wells Notice","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.9M in Q4 2024 vs net income of $51.2M in Q4 2023; diluted EPS loss of $(0.38).","Total revenue fell to $15.0M from $73.5M YoY, driven by lower collaboration revenue from GSK and Pfizer.","Tebipenem HBr Phase 3 PIVOT-PO interim analysis expected Q2 2025; SPR720 Phase 2a missed primary endpoint with three cases of grade 3 hepatotoxicity; SPR206 discontinued.","Leadership change: Esther Rajavelu appointed Interim President and CEO in January 2025 following a Wells Notice from SEC related to disclosures in 2022.","Cash of $52.9M as of Dec 31, 2024; plus GSK milestones provide runway into Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176511,"accession_number":"0001193125-25-042785","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Spero Therapeutics receives Nasdaq bid price deficiency notice; has until Aug 25, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Spero on Feb 25, 2025 that its stock closed below $1.00 for 30 consecutive trading days.","Compliance deadline is August 25, 2025; cure requires closing at $1.00+ for 10 consecutive business days.","If not cured, Spero may transfer to Nasdaq Capital Market and consider reverse stock split for 180-day extension.","Stock continues trading on Nasdaq GS under SPRO; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176510,"accession_number":"0001193125-25-004063","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","5.02","8.01","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.","CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.","Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.","Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.","Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193365,"accession_number":"0001193125-24-258540","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.","Phase 3 PIVOT-PO trial of tebipenem HBr on track to complete enrollment in 2H 2025 (target ~2,648 patients).","SPR720 program suspended after Phase 2a missed primary endpoint; three cases of reversible grade 3 hepatotoxicity.","Cash and equivalents $76.3M; Oct 2024 restructuring and ~39% RIF extend cash runway into mid-2026.","SPR206 IND cleared for Phase 2 in HABP/VABP, but initiation contingent on non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":32933000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193364,"accession_number":"0001193125-24-246627","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","2.05","7.01","8.01","9.01"],"status":"ready","headline":"Spero suspends SPR720 development after Phase 2a miss; cuts workforce 39%, extends cash runway to mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPR720 Phase 2a interim analysis did not meet primary endpoint; 3 cases of reversible grade 3 hepatotoxicity at 1,000 mg dose.","Company restructuring with ~39% workforce reduction; expects ~$1.1M in cash restructuring charges.","Unaudited Q3 2024 cash ~$76.3M; cash runway extended into mid-2026.","Tebipenem HBr PIVOT-PO Phase 3 trial on track for enrollment completion in 2H 2025.","IND cleared for SPR206 Phase 2 trial in HABP/VABP, contingent on non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209710,"accession_number":"0001193125-24-216310","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Spero Therapeutics updates investor presentation; no material new financial or operational data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated investor presentation dated September 9, 2024, under Regulation FD.","Presentation available on Spero's IR website; company disclaims obligation to update after that date.","No specific financial metrics, pipeline updates, or guidance changes were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209709,"accession_number":"0001193125-24-193913","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.","Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.","SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.","CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.","Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":19464000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227852,"accession_number":"0001193125-24-153034","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Spero Therapeutics shareholders approve 3M share increase for 2017 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Stock Incentive Plan, adding 3,000,000 authorized shares.","All three Class I director nominees (Scott Jackson, John C. Pottage Jr., Cynthia Smith) were reelected.","Ratification of PricewaterhouseCoopers as auditor for FY2024 passed with 36.6M votes for.","Advisory vote on executive compensation approved (23.9M for, 442k against).","Quorum of 68.23% of outstanding shares present at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227851,"accession_number":"0001193125-24-139364","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.","Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.","SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.","SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.","Reaffirmed cash runway into late 2025 based on current operating plans."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":9267000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246646,"accession_number":"0001193125-24-082060","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Spero Therapeutics sets 2024 Annual Meeting for May 29, 2024 (online)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting on May 29, 2024, will be held entirely online via virtual format.","Meeting scheduled more than 30 days before prior year's meeting (Oct 5, 2023), triggering special notice under Bylaws.","Stockholders should review Bylaws for deadlines on Rule 14a-8 proposals and director nominations.","Proxy statement will detail online attendance, voting, and question submission procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246645,"accession_number":"0001193125-24-066825","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).","Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.","Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.","SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.","Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}